Intern: Digital & Quantitative Medicine
Posted on: 3 Apr 2021
Cambridge, MA
Job Description
Company Description
At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the worlds first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
Job Description
This position is for a 12 week internship from June - August 2021
The Clinical Assessments Group of Digital & Quantitative Medicine (DQM) at Biogen seeks a talented intern to join our team that is responsible for developing a rigorous paradigm for improving clinical trial outcomes. Our group assesses platforms in clinical technologies, quantitative medicine, and experimental medicine and relies on robust interfaces with groups across the organization.
At Biogen, we are pioneers. Millions of people around the world are affected by multiple sclerosis, Alzheimers disease, Parkinsons disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders. Many also suffer from less common diseases such as spinal muscular atrophy (SMA). We believe there is still much need for medical breakthroughs in these and related diseases.
Biogen has some of the worlds best biomedical researchers. We engage with physicians and scientific leaders around the world with the aim to further biomedical research. Our focus on neuroscience and immunology, deep scientific expertise and courage to take appropriate risks make us leaders in the research and development of medicines to benefit society.
Qualifications
The position requires familiarity with analysis and interpretation of experimental results. The individual will be expected to work collaboratively with team members and groups across Biogen. The project will focus on health equity by developing disease-specific plans for ensuring access for underrepresented groups and exploring elements of the patient journey that help us better understand the scientific basis for responses to therapies.
To participate in the Biogen Internship Program, students must meet the following eligibility criteria:
* Legal authorization to work in the U.S.
* Grade point average of 3.2 or higher preferred
* At least 18 years of age prior to the scheduled start date
* Be currently enrolled in an accredited college or university
The successful candidate will have experience in biological understanding of human disease and an interest in clinical trials.
Education:
Degree-seeking college coursework in a scientific field required
Additional Information
All your information will be kept confidential according to EEO guidelines.
Biogen
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
-
IndustryBiotechnology
-
No. of Employees7,800
-
Website
-
Jobs Posted445
